Compare MDV & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MDV | MOLN |
|---|---|---|
| Founded | 2015 | 2004 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Transportation Services | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 157.4M | 158.9M |
| IPO Year | 2022 | 2021 |
| Metric | MDV | MOLN |
|---|---|---|
| Price | $15.04 | $4.57 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.38 |
| AVG Volume (30 Days) | ★ 35.2K | 6.8K |
| Earning Date | 03-03-2026 | 03-05-2026 |
| Dividend Yield | ★ 7.89% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $47,479,000.00 | N/A |
| Revenue This Year | $0.13 | N/A |
| Revenue Next Year | $0.71 | $999.99 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $13.62 | $3.36 |
| 52 Week High | $17.15 | $5.15 |
| Indicator | MDV | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 56.05 | 60.98 |
| Support Level | $14.93 | $4.01 |
| Resistance Level | $15.51 | $4.28 |
| Average True Range (ATR) | 0.34 | 0.18 |
| MACD | 0.04 | 0.05 |
| Stochastic Oscillator | 65.22 | 70.59 |
Modiv Industrial Inc is a pioneer in the direct-to-consumer commercial real estate product industry. It provides individual investors access to real estate and real estate-related investments designed to provide both income and long-term growth. The Company has invested in single-tenant income-producing properties. Its current business consists of owning, managing, operating, leasing, acquiring, investing in and disposing of commercial real estate assets utilized for industrial manufacturing, as well as a few non-core assets. All of the company's consolidated revenues are derived from company's consolidated real estate properties.
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.